GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (MEX:FGEN) » Definitions » Cyclically Adjusted PS Ratio

FibroGen (MEX:FGEN) Cyclically Adjusted PS Ratio : 0.48 (As of Jun. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is FibroGen Cyclically Adjusted PS Ratio?

As of today (2024-06-25), FibroGen's current share price is MXN20.14. FibroGen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was MXN42.14. FibroGen's Cyclically Adjusted PS Ratio for today is 0.48.

The historical rank and industry rank for FibroGen's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:FGEN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.14   Med: 0.65   Max: 8.47
Current: 0.4

During the past years, FibroGen's highest Cyclically Adjusted PS Ratio was 8.47. The lowest was 0.14. And the median was 0.65.

MEX:FGEN's Cyclically Adjusted PS Ratio is ranked better than
92.46% of 504 companies
in the Biotechnology industry
Industry Median: 5.225 vs MEX:FGEN: 0.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

FibroGen's adjusted revenue per share data for the three months ended in Mar. 2024 was MXN9.373. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN42.14 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


FibroGen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for FibroGen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Cyclically Adjusted PS Ratio Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 5.52 0.32

FibroGen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.40 0.93 0.31 0.32 0.83

Competitive Comparison of FibroGen's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, FibroGen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where FibroGen's Cyclically Adjusted PS Ratio falls into.



FibroGen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

FibroGen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=20.14/42.14
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FibroGen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, FibroGen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9.373/131.7762*131.7762
=9.373

Current CPI (Mar. 2024) = 131.7762.

FibroGen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 24.679 100.560 32.340
201409 3.295 100.428 4.324
201412 4.023 99.070 5.351
201503 4.197 99.621 5.552
201506 27.511 100.684 36.007
201509 5.433 100.392 7.131
201512 6.826 99.792 9.014
201603 7.829 100.470 10.268
201606 23.921 101.688 30.999
201609 9.260 101.861 11.980
201612 11.562 101.863 14.957
201703 8.657 102.862 11.090
201706 7.857 103.349 10.018
201709 9.697 104.136 12.271
201712 7.339 104.011 9.298
201803 7.000 105.290 8.761
201806 10.312 106.317 12.781
201809 6.425 106.507 7.949
201812 24.929 105.998 30.992
201903 5.401 107.251 6.636
201906 40.116 108.070 48.916
201909 7.527 108.329 9.156
201912 1.721 108.420 2.092
202003 6.486 108.902 7.848
202006 11.067 108.767 13.408
202009 10.384 109.815 12.461
202012 14.181 109.897 17.004
202103 8.567 111.754 10.102
202106 5.256 114.631 6.042
202109 34.556 115.734 39.346
202112 3.658 117.630 4.098
202203 13.017 121.301 14.141
202206 6.415 125.017 6.762
202209 3.375 125.227 3.552
202212 7.125 125.222 7.498
202303 6.883 127.348 7.122
202306 7.775 128.729 7.959
202309 7.116 129.860 7.221
202312 4.676 129.419 4.761
202403 9.373 131.776 9.373

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FibroGen  (MEX:FGEN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


FibroGen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of FibroGen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (MEX:FGEN) Business Description

Industry
Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.